Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

BackgroundImmune checkpoint inhibitors (ICIs) plus chemotherapy improved the prognosis of patients with non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers are lacking. We explored factors associated with prognosis and developed a predictive model.MethodsWe retrospectively an...

Full description

Bibliographic Details
Main Authors: Hao Zeng, Wei-wei Huang, Yu-jie Liu, Qin Huang, Sheng-min Zhao, Ya-lun Li, Pan-wen Tian, Wei-min Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
chemotherapy
non-small cell lung cancer (NSCLC)
nomogram
progression-free survival (PFS)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.685047/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.685047/full

Similar Items